Andrew Ambrosy to Enalapril
This is a "connection" page, showing publications Andrew Ambrosy has written about Enalapril.
Connection Strength
0.790
-
Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. JACC Heart Fail. 2020 10; 8(10):859-866.
Score: 0.185
-
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. J Am Coll Cardiol. 2020 09 01; 76(9):1034-1048.
Score: 0.184
-
Improving physical activity and exercise capacity in heart failure. Taking the first step is always the hardest. Eur J Heart Fail. 2020 09; 22(9):1734-1736.
Score: 0.183
-
Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. Am Heart J. 2018 04; 198:145-151.
Score: 0.153
-
Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. JAMA Cardiol. 2020 02 01; 5(2):202-207.
Score: 0.044
-
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 02 07; 380(6):539-548.
Score: 0.041